CClinicalTrials.gg
CompletedNCT05577897Updated Oct 13, 2022

Effectiveness of Education Given to Patients With COPD

An interventional study of Education in COPD, sponsored by Zeynep Yildirim. Completed at 1 site in Turkey. Per ClinicalTrials.gov, last updated 2022-10-13.

Sponsored by Zeynep Yildirim · Not applicable, Interventional, and Supportive care

From the registry’s dates

  • Registered 1 year 9 months after the study started (first participant enrolled Dec 2020, registered Sep 2022).
Phase
Not applicable
Study type
Interventional
Enrollment
83
Allocation
Randomized
Sex
All
01

Study summary

This study was conducted to examine the effects of chronic obstructive pulmonary disease management education given to patients diagnosed with chronic obstructive pulmonary disease on self-care agency and rational drug use. This study has a pretest-posttest quasi-experimental design. A total of 83 patients with COPD were randomly assigned to a intervention group or control group, who met the inclusion criteria.

Read the detailed description

COPD, which is one of the most common respiratory system diseases, is an important global health problem. Chronic Obstructive Pulmonary Disease (COPD), which is a disease with significant mortality and morbidity, is characterized by progressive air flow obstruction; it is irreversible and accompanied by multiple symptoms and frequent exacerbations. Among the leading causes of death, COPD is in the fourth place in the world, while it is in the third place in our country.

At the end of the physiopathological processes that occur in COPD, respiratory function is severely impaired, and individuals experience significant levels of limitations while performing their daily living activities due to shortness of breath, cough, fatigue and insomnia. Long-term drug therapy is used commonly to control these limitations in patients with COPD. Increased dyspnea, activity intolerance, long lasting oxygen and drug therapy, social intolerance and chronic hypoxia cause a decrease in the quality of life and psychological problems. It is important for patients to have sufficient level of self-care agency and to take responsibility for their self-care to control COPD symptoms. Self-care management consists of behaviors performed to manage the symptoms of the disease or to manage the side effects of the treatment. In patients with COPD, self-care is specifically important since it can improve health-related quality of life and decrease hospitalization and dispnea.

One of the necessary steps to improve the symptoms and limitations caused by the physiopathological processes that occur in COPD is drug therapy. A large number of drug groups are used in COPD treatment. The aim of drug therapy in COPD is eliminating the symptoms, improving exercise tolerance and health status and increasing future risks (prevention and treatment of attacks, prevention of disease progression and decrease in mortality). Stable COPD treatment should be individualized depending on the symptoms of patients. In patients with COPD, the problem of compliance with medication due to reasons such as insufficient or no training on medication, cognitive or physical insufficiency of patients, educational and sociocultural level difference of patients, not choosing the device suitable for patients, misuse of drug, or the inability to use the drug are very common among patients. Patients should be able to transform rational drug use into behavior and have the required knowledge and attitude levels. In this context, the responsibility of nurses for educating and informing patients emerges.

Education is very important in terms of improving the self-care skills of patients with COPD, increasing their functional abilities, using drugs properly, managing the disease processes and improving quality of life. The effects of the education given on different parameters have been evaluated in literature. Therefore, it is thought that the education given to patients about COPD management may contribute to increasing the self-care agency of the patient and to rational use of drugs. This study was conducted to find out the effects of COPD management education given to patients diagnosed with COPD on self-care agency and rational drug use.

02

Conditions studied

  • COPD

Keywords

  • Patient education
  • Nurse
  • COPD
  • Self-care agency
  • Rational drug use
03

In context

Lead sponsor

Zeynep Yildirim is the lead sponsor of 4 studies on the registry; 2 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
Child (0–17), Adult (18–64), Older adult (65+)
Sexes eligible
All
Accepts healthy volunteers
Yes

Inclusion criteria

  • Patients who had been receiving CODP treatment for longer than 6 months
  • Patients who had low or moderate levels of self-care agency
  • Patients who needed to use medication continuously to treat COPD
  • Patients who had no sensory loss related to hearing and vision
  • Patients who were open to cooperation and communication and who were oriented

Exclusion criteria

Exclusion Criteria:

  • Patients who left the study at any stage
  • Patients who had been receiving CODP treatment for less than 6 months
05

Study design

Phase
Not applicable
Primary purpose
Supportive care
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
83 participants (actual)

Study arms

  • Experimental
    Patient Education

    The intervention group was given 45 minutes of training.

    Other: Education

  • No intervention
    Control Group

    Routine nursing care was given to the patients in this group without any training.

Interventions

  • OtherEducation

    A separate room in Chest Diseases Clinic was used for the education of the patients in this group for a quiet environment and for the education not to be interrupted. The education of a patient lasted approximately 45 minutes. The education booklet "COPD Guide" on COPD management prepared in line with the literature was given to the patients by the researcher. After the content of the education was explained to the patients, 45-minute of education was given through face-to-face verbal presentation and demonstration method.

06

What researchers measure

Primary outcomes

  1. Self Care Agency Scale

    SCAS was developed by Kearney and Fleischer. It was adapted into Turkish by by Nahcivan on healthy young individuals and by Pınar on chronic diseases. SCAS has 35 questions with answers on a 5-point, Likert-type scale (from 1 to 5). A total score below 82 is evaluated as low level of self-care agency, while total score between 82 and 120 is evaluated as moderate level of self-care agency and a total score higher than 120 is evaluated as high level of self-care agency.

    Time frame: up to 6 weeks

  2. Rational Drug Use Scale

    RDUS was developed by Demirtaş et al. to determine rational drug use knowledge levels of adult patients. The 3 Likert-type scale consists of a total of 21 expressions, 10 correct and 11 incorrect. The answers given; Correct answer is scored as 2, I don't know 1, and wrong answer is 0 points. Maximum possible score of the scale is 42. A total score of 35 and higher is evaluated as having rational drug use knowledge.

    Time frame: up to 6 weeks

07

Study locations

1 site
  • Zeynep YILDIRIM
    Erzurum, Yakutiye 25100, Turkey
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on Oct 13, 2022, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT05577897
Lead sponsor
Zeynep Yildirim
Responsible party
Zeynep Yildirim (Research Assistant, Ataturk University) — Sponsor-investigator
First posted
Oct 13, 2022
Start date
Dec 11, 2020
Primary completion
Jun 25, 2021
Completion
Jul 12, 2021
Last update
Oct 13, 2022

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Oct 2022. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion